Vaxart (VXRT) Reports First Patient Enrollment in Phase 1b Norovirus Boosting Regimen Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Vaxart Announces First Subject Enrolled in Phase 1b Norovirus Boosting Regimen Study
May 4, 2021 8:00 AM EDTStudy will evaluate safety and immunogenicity of multiple distinct dosing regimens of norovirus oral vaccine candidate
Norovirus infects 15% of U.S. children under age five every year
Study results may inform the COVID-19 oral vaccine program
SOUTH SAN FRANCISCO, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has enrolled the first subject in a Phase 1b boosting regimen trial of... More
